Abstract
Low levels of reactive oxygen species (ROS) are crucial for maintaining cancer stem cells (CSCs) and their ability to resist therapy, but the ROS regulatory mechanisms in CSCs remains to be explored. Here, we discover that prohibitin (PHB) specifically regulates mitochondrial ROS production in glioma stem-like cells (GSCs) and facilitates GSC radiotherapeutic resistance. We find that PHB is upregulated in GSCs and is associated with malignant gliomas progression and poor prognosis. PHB binds to peroxiredoxin3 (PRDX3), a mitochondrion-specific peroxidase, and stabilizes PRDX3 protein through the ubiquitin-proteasome pathway. Knockout of PHB dramatically elevates ROS levels, thereby inhibiting GSC self-renewal. Importantly, deletion or pharmacological inhibition of PHB potently slows tumor growth and sensitizes tumors to radiotherapy, thus providing significant survival benefits in GSC-derived orthotopic tumors and glioblastoma patient-derived xenografts. These results reveal a selective role of PHB in mitochondrial ROS regulation in GSCs and suggest that targeting PHB improves radiotherapeutic efficacy in glioblastoma.
Introduction
Glioblastoma (GBM) remains one of the most lethal human brain tumors, largely due to its profound resistance to ionizing radiation. This therapeutic resistance is driven by a subpopulation known as glioma stem-like cells (GSCs). To maintain their self-renewal capacity and survive the oxidative stress induced by radiation, GSCs must keep mitochondrial reactive oxygen species (ROS) at very low levels. While general antioxidant pathways are known, identifying a GSC-specific regulator is critical for developing targeted therapies that spare healthy brain tissue.
PHB as a GSC-Specific Regulator
Through proteomic screening and bioinformatic analysis of patient datasets, researchers identified Prohibitin (PHB) as a key protein enriched in GSCs. Unlike many mitochondrial proteins, PHB expression is significantly higher in GSCs than in differentiated tumor cells or normal neural cells.
Western blot analysis confirms that PHB and its partner PHB2 are consistently upregulated in GSCs across multiple patient-derived lines. This expression pattern mirrors that of core stemness factors such as SOX2 and Olig2, while being inversely related to the differentiation marker GFAP.
The PHB-PRDX3 Mechanism
The study elucidates a novel mechanism where PHB acts as a chaperone for Peroxiredoxin3 (PRDX3), a mitochondrion-specific peroxidase. PHB physically interacts with PRDX3, preventing its ubiquitination and subsequent degradation. In the absence of PHB, PRDX3 levels decline, leading to an accumulation of mitochondrial ROS. This oxidative stress triggers a gene expression program (including ATF3 and DDIT3) that promotes GSC differentiation and apoptosis.
Clinical Significance and Therapeutic Potential
The clinical relevance of PHB is supported by data from the Gene Expression Omnibus (GEO) and direct examination of patient tissues. PHB levels are significantly elevated in GBM tissue compared to adjacent healthy brain tissue, and high expression is a predictor of poor prognosis and tumor recurrence.
Targeting this pathway offers a promising therapeutic window. The PHB inhibitor Rocaglamide A (RocA) demonstrated high potency against GSCs (IC50 < 5 nM) with minimal toxicity to normal cells. Most importantly, pharmacological or genetic inhibition of PHB sensitized tumors to radiotherapy. In animal models, the combination of PHB suppression and radiation significantly extended median survival compared to monotherapy.
Conclusion
This study identifies PHB as a selective and essential regulator of mitochondrial ROS in GSCs. By stabilizing PRDX3, PHB maintains the low-ROS environment necessary for GSC survival and therapeutic resistance. These findings suggest that targeting the PHB-PRDX3 axis could be a viable strategy to enhance the efficacy of radiotherapy in glioblastoma patients.
Summary updated